Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864108 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL13056339 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL15144368 | 0.91 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL14728251 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL18081560 | 0.90 | ALDH1A1 (0.37) | SMN1; SMN2HPGDHTTTSHRPOLB | |
| SCHEMBL24686922 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL14980037 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL277693 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDHTTTSHRCYP2C19 | |
| SCHEMBL14755921 | 0.86 | ALDH1A1 (0.35) | SMN1; SMN2HPGDHTTTSHRPOLB | |
| SCHEMBL16328730 | 0.86 | ALDH1A1 (0.39) | SMN1; SMN2HPGDHTTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-8106131-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100113329-A1 | Maleamic Acid Polymer Derivatives and Their Bioconjugates | NEKTAR THERAPEUTICS (US) | 2010-05-06 | — | — | US | disclosed |
| US-7659361-B2 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080146771-A1 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS | 2008-06-19 | — | — | US | disclosed |
| US-7329721-B2 | Maleamic acid polymer derivatives and their bioconjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | IL2, IL2RA, ILF2 | SMN1; SMN2 3123/4885HPGD 712/4885HTT 3288/4885 |
| US-20100113329-A1 | Maleamic Acid Polymer Derivatives and Their Bioconjugates | F13A1, ASS1, PSAT1 | SMN1; SMN2 867/4885HPGD 1539/4885HTT 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.